Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKIN.L Regulatory News (SKIN)

  • There is currently no data for SKIN

Trading Update

15 Nov 2018 07:00

RNS Number : 4061H
Integumen PLC
15 November 2018
 

 

15 November 2018

 

Integumen plc

 

("Integumen" or "the Company")

 

Trading Update

 

 

The Company is pleased to announce the increased growth in product sales and contract test services at Labskin (Innovenn Limited, a wholly-owned subsidiary of Integumen plc).

 

With improved visibility ahead, the Company is on track to meet or exceed double the Group's revenues from the 2017 (£238,000) level. This is as a result of increased sales of STOER For Men skin products and the reduced marketing spend, leading to the current monthly break-even in the Skin Care division.

 

Major Restructuring:

 

Labskin, the trading name of Innovenn Limited, has undergone a major restructuring due to the acceleration of sales and services since H1 2018. A new website is now live at www.labskin.co.uk and reflects the new services being provided to its existing and new client base. Clients range from early start-up biotech companies to Fortune 100 companies with household name, health and cosmetic, brands.

 

Positive Results:

 

Improved revenue since July 2018 from Labskin has already been reported back in September as multiples of the entire H1 2018 reported sales (£49,000). Monthly sales continue to improve and further information on these improvements and expectation of where additional revenues are expected to come from are outlined below.

 

Artificial Intelligent Skin Care:

 

The recently announced collaboration with Venn Life Sciences Holdings plc and RinoLab, expected to go live shortly, delivers an integrated Artificial Intelligent product development platform for clients that allow validation of the impact of their product on the good and bad bacteria on human skin.

 

Balanced Microbiome Labskin Certified:

 

Confirmation of Labskin test results showing a balanced microbiome that contributes a positive outcome to skin treatment can now be certified for our clients' cosmetic and skin care products.

 

First Labskin Certified Range of Cosmetics:

 

STOER For Men, a skin care range of products owned by Integumen, are the first skin care products that have been certified as having a positive contribution to balancing skin's microbiome. They will be sold with the Labskin Certification. The low sales of STOER skin care products, with a high cost of sales, in H1 have improved in H2 2018. Monthly sales of STOER are at breakeven and expected to continue to improve into 2019.

 

Association of Labskin Certified Technicians:

 

Preparations are underway to roll out the Association of Labskin Certified Technicians (ALCT). Workshops and courses will commence in Q1 2019. Interest for certification already exists from our recent and new clients. These applied certified course programs serve to improve the expertise of our clients' in-house Labskin scientists, and increases the exposure of the Labskin brand test platform across the skin, health, topical drug delivery and wound care sectors.

 

New Appointments and Promotions:

 

Head of Labskin Operations:

 

Alex Chapman, has been promoted to lead an expanding team at Labskin. Alex joined Labskin in 2017 and was until recently General Manager of the Labskin team. This has now expanded in both production and tissue culture departments with a number of additional personnel since August. Labskin will add up to 40% more laboratory space in 2019 and Alex will also oversee external contract providers of third party-services which allows Labskin to provide a fully inclusive pre-clinical service solution to our clients.

 

Laboratory & Operations Manager:

 

Rupert Petch joins the Labskin team as laboratory and operations manager. Rupert worked as Project Manager for Fera Science Limited and its former company name of CSL (Central Science Laboratory) for almost 19 years. He is overseeing the expansion of the laboratory team and building on the solid foundation of quality controls to meet the highest standards required of our increasing client base.

 

 

Gerard Brandon (Chief Executive Officer) commented:

"In just the last 3 months the improvement of the Labskin and STOER Skin Care divisions have been transformational. Sales have accelerated and costs have reduced to breakeven in the skincare section. Labskin's new high margin services have seen higher demand with improved revenues from cosmetic, skin, health and wound care companies. There is good visibility of orders for the months ahead. Recent collaboration partners allow Labskin to roll out new products and value added services faster to our existing and new clients. This boost in sales has resulted in a need to add team members to support the increasing demand."

 

Integumen plc

Gerard Brandon, CEO

 

+44 (0) 122 392 6660

SPARK Advisory Partners Limited

(Nominated Adviser)

 

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Hybridan LLP (Broker)

Claire Noyce

+44 (0) 20 3764 2341

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTKMMMMLDDGRZM
Date   Source Headline
28th Apr 20204:37 pmRNSPrice Monitoring Extension
28th Apr 20202:05 pmRNSSecond Price Monitoring Extn
28th Apr 20202:00 pmRNSPrice Monitoring Extension
17th Apr 20202:06 pmRNSSecond Price Monitoring Extn
17th Apr 20202:00 pmRNSPrice Monitoring Extension
30th Mar 20207:00 amRNSUpdate re COVID 19; confirmed orders; investment
23rd Mar 20207:00 amRNSDirector/PDMR Shareholding
18th Mar 202010:22 amRNSDirector/PDMR Shareholding
18th Mar 20207:00 amRNS3 year $3.75m (£3.12m) bacteria prod'n agreement
12th Mar 20202:06 pmRNSSecond Price Monitoring Extn
12th Mar 20202:00 pmRNSPrice Monitoring Extension
26th Feb 20207:00 amRNSLaunch of ecowaterOS; Company Update
7th Feb 20207:00 amRNSIntegumen plc to present at The UK Investor Show
3rd Feb 20207:00 amRNSCommercial & AI partnership with Acumen Software
21st Jan 20207:00 amRNSCooperative Alliance; Trading Update
19th Dec 20197:00 amRNS3-year Rev sharing Framework Ag with Parity Group
16th Dec 20198:43 amRNSDirector/PDMR Shareholdings
9th Dec 201911:05 amRNSPlacing/Subscription to raise £1.368m -replacement
9th Dec 20197:00 amRNSPlacing and subscription to raise £1.368 million
20th Nov 20197:00 amRNSResults of AI water research project
13th Nov 20197:00 amRNSHeads of Terms -Framework Agreement;trading update
7th Nov 20197:00 amRNSMicrobiome and Labskin clone R&D agreements signed
29th Oct 20197:00 amRNSLaunch of ind. Rinodrive AI open-source eco-system
21st Oct 20197:00 amRNSRinocloud subsidiary wins "One To Watch" IT award
8th Oct 201912:34 pmRNSIssue of Equity: Shares in Lieu of Invoice
7th Oct 20197:00 amRNSLabskinAI creates virtual AI psoriasis skin model
7th Oct 20197:00 amRNSLabskin signs multi-year service agreement
11th Sep 20197:00 amRNSInterim Results
5th Sep 20197:00 amRNSLabskin breakthrough clones 16 human skin swabs
2nd Aug 20197:00 amRNSHighlands Nat. Resources agreement with Cellulac
1st Aug 20191:41 pmRNSExercise of Warrants
1st Aug 201911:32 amRNSExercise of Warrants
31st Jul 20194:30 pmRNSResult of AGM
31st Jul 20197:00 amRNSAGM - Trading Update
29th Jul 20197:00 amRNSCollaboration; Expansion of wound care division
19th Jul 20197:00 amRNSLabskinAI:agreementswith global cosmetic companies
12th Jul 20197:00 amRNSChange to interests of a significant shareholder
11th Jul 201910:38 amRNSExercise of Warrants (update)
10th Jul 201912:55 pmRNSExercise of warrants
8th Jul 20197:00 amRNSAGM Notice and Trading Update
28th Jun 20193:03 pmRNSExercise of Warrants
27th Jun 20197:00 amRNSFinal Results
21st Jun 20197:00 amRNSExercise of Warrants
20th Jun 20197:01 amRNSExecutive team and Labskin AI digital hub updates
20th Jun 20197:00 amRNSExercise of Warrants
10th Jun 20197:00 amRNSExercise of Warrant Shares and Call Option Shares
28th May 20197:30 amRNSExercise of Warrants
28th May 20197:00 amRNSNew Labskin AI contracts; additional lab space
21st May 20197:00 amRNSTrading update and Board changes
10th May 201912:19 pmRNSLaunch of Labskin human skin clone tests

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.